PCSK9抑制剂治疗颅内动脉粥样硬化相关急性缺血性卒中 (PISTIAS-3)
2026年7月14日 更新者:Wei-Hai Xu、Peking Union Medical College Hospital
PCSK9抑制剂治疗颅内动脉粥样硬化相关急性缺血性卒中(PISTIAS-3):一项随机、双盲、安慰剂对照试验
本研究是一项前瞻性、多中心、双盲、随机、安慰剂对照临床试验,旨在评估早期给予PCSK9抑制剂是否能有效改善颅内动脉粥样硬化性狭窄(ICAS)相关缺血性脑卒中(AIS)患者90天的功能预后,主要采用90天改良Rankin量表进行评估。
研究概览
地位
尚未招聘
详细说明
急性缺血性卒中(AIS)仍然是全球范围内导致死亡和残疾的主要原因之一。
尽管静脉溶栓和血管内治疗显著提高了再灌注成功率,但在临床实践中仍存在三个决定预后的关键挑战:首先,只有有限比例的患者能在治疗时间窗内实际接受再灌注治疗;其次,即使再灌注成功,仍可能发生微循环灌注障碍、炎症级联反应和血栓再形成等继发性损伤。
第三,急性期波动,特别是早期神经功能恶化和早期复发风险,仍然突出,直接限制了功能结局的改善。
3 在中国,颅内动脉粥样硬化性狭窄(ICAS)占缺血性卒中病因的50%之多。
其病理链——“斑块不稳定性-血栓形成-微循环障碍”——贯穿急性和亚急性期,与早期复发和不良结局密切相关。前蛋白转化酶枯草溶菌素9(PCSK9)经典地促进低密度脂蛋白胆固醇(LDL-C)受体的降解并升高LDL-C水平,从而驱动动脉粥样硬化进展。
更重要的是,越来越多的基础和转化研究表明,PCSK9可能不仅作为“脂质代谢蛋白”发挥作用,还参与内皮激活、炎症级联反应、血小板反应性和微循环功能障碍等过程。
这使其成为连接“斑块-血栓-炎症”轴的潜在枢纽。
因此,在急性缺血性卒中(AIS)的急性期,PCSK9抑制剂可能提供超越降脂作用的额外神经血管保护益处。现有的基础和临床证据表明,通过脂质依赖性和非脂质依赖性途径的双重机制,PCSK9抑制剂可能在AIS急性期对驱动动脉粥样硬化的关键病理过程发挥联合干预作用。
机制研究表明,抑制PCSK9同时调节炎症反应、内皮激活、功能障碍和血栓形成倾向。
在缺血-再灌注模型中,它通过减轻脑损伤和改善神经功能显示出神经保护信号。
临床上,大型随机试验证实其能够快速增强他汀类药物之外的降脂效果并降低缺血性卒中风险。
脑血管疾病的进一步转化证据表明,在有症状的ICAS人群中,PCSK9抑制剂联合他汀类药物强化降脂治疗可减少斑块负荷、缓解狭窄并增加斑块稳定性。
在AIS的急性期,早期加用PCSK9抑制剂与7天内神经功能恶化减少、30天内复发风险降低以及90天功能结局改善相关。
总之,这一从机制到临床实践的完整证据链为在ICAS相关AIS治疗中加用PCSK9抑制剂提供了明确的科学依据和临床必要性。本研究是一项全国性、前瞻性、多中心、双盲、随机、安慰剂对照的临床试验。
它将纳入1212名符合纳入和排除标准的患者。
患者将使用随机分配方法随机分配到两组:(1)实验组:注射用瑞卡替单抗450毫克(3瓶)单次皮下注射给药。
(2)对照组:注射用瑞卡替单抗安慰剂450毫克(3瓶)单次皮下注射给药。
每组将包括606名患者。
除研究药物外,两组都将接受标准指南推荐的治疗。
长期疗效通过患者在0小时、24小时(±2或±12小时)、7天(±2天)或出院时、90天(±7天)和1年时的访视和评估进行评估。主要结局指标包括:基于意向治疗原则,使用ANCOVA模型对所有随机化患者进行分析,这些患者在基线时进行了高分辨率磁共振成像(HRMRI)且在90天时改良Rankin量表(mRS)评分为0-2分。
次要结局指标包括:(1)90天时mRS评分为0-1分(表示患者功能良好);(2)90天mRS评分的分布;(3)90天内任何卒中(包括缺血性和出血性);(4)90天内缺血性卒中;(5)90天内复合血管事件(包括卒中、心肌梗死和血管性死亡);(6)90天欧洲五维健康量表(EQ-5D-5L)评分;(7)90天巴氏指数(BI)评分。详细信息见“结局指标”部分。样本量基于主要结局计算,预计总共纳入1212名参与者。
一个独立的数据安全监查委员会将监督试验的整体实施。
研究类型
介入性
注册 (估计的)
1212
阶段
- 第四阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Yiyang Liu, PhD
- 电话号码:86+13938912070
- 邮箱:liuyydoct@163.com
研究联系人备份
- 姓名:Weihai Xu, MD
- 电话号码:86+13938912070
- 邮箱:xuwh@pumch.cn
学习地点
-
-
-
Beijing、中国
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing 100730
-
接触:
- Weihai Xu, MD
- 电话号码:86+13651147766
- 邮箱:xuwh@pumch.cn
-
首席研究员:
- Weihai Xu, MD
-
Chongqing、中国
- Chongqing General Hospital
-
Shanghai、中国
- Huashan Hospital, Fudan University
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100853
- Chinese PLA General Hospital
-
接触:
- Shiwen Wu, MD
- 电话号码:86+13910238117
- 邮箱:wu_shiwen@outlook.com
-
首席研究员:
- Shiwen Wu, MD
-
-
Guangdong
-
Meizhou、Guangdong、中国
- The Third Affiliated Hospital of Sun Yat-sen University, Yuedong Hospital
-
-
Hebei
-
Cangzhou、Hebei、中国
- Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine
-
Qinhuangdao、Hebei、中国
- Peking University Third Hospital Qinhuangdao Hospital
-
Shijiazhuang、Hebei、中国、050051
- Hebei Provincial People's Hospital
-
Tangshan、Hebei、中国、063000
- Tangshan Worker's Hospital
-
接触:
- Baoquan Lu
- 电话号码:13930565557
- 邮箱:balcom@163.com
-
首席研究员:
- Baoquan Lu, MD
-
-
Heilongjiang
-
Harbin、Heilongjiang、中国
- First Affiliated Hospital of Harbin Medical University
-
-
Henan
-
Zhengzhou、Henan、中国
- The First Affiliated Hospital of Zhengzhou University
-
-
Hubei
-
Shiyan、Hubei、中国
- Affiliated Taihe Hospital of Hubei University of Medicine
-
Wuhan、Hubei、中国
- Zhongnan Hospital of Wuhan University
-
-
Inner Mongolia
-
Baotou、Inner Mongolia、中国、014000
- Baotou Central Hospital
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210000
- Nanjing First Hospital
-
-
Shandong
-
Jining、Shandong、中国、272000
- Jining First People's Hospital
-
Liaocheng、Shandong、中国、252000
- Liaocheng People's Hospital
-
Qingdao、Shandong、中国
- The Affiliated Hospital of Qingdao University
-
Weifang、Shandong、中国、261000
- Weifang People's Hospital
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
纳入标准:
- 年龄≥30岁且≤80岁
- 急性缺血性卒中发作72小时内(通过CT/MRI结合神经功能缺损症状确定)
- 入院时NIHSS评分为4-25分
- 影像学检查(CTA/DSA/MRA)支持颅内动脉粥样硬化是卒中原因,符合以下任一标准:i.责任血管存在颅内动脉粥样硬化性狭窄(ICAS),狭窄程度为50-99%;ii.责任血管存在颅内动脉粥样硬化性闭塞(ICAS-LVO),通过机械取栓成功实现血管再通(即刻扩大脑梗死溶栓[eTICI]分级2b50-3)
- 已签署知情同意书
排除标准:
- 非动脉粥样硬化性颅内动脉狭窄(如动脉夹层、烟雾病、系统性血管炎等)
- 任何可识别的心源性栓塞来源(如心房颤动、机械瓣膜、左心室血栓、卵圆孔未闭等)
- 影像学表现和临床症状提示本次事件的主要病理生理更符合脑小血管病(如穿支动脉闭塞/腔隙性梗死)
- 本次缺血事件发生前已存在残疾(改良Rankin量表评分≥2分)
- CT或MRI检查提示大面积脑梗死(如ASPECTS评分<6分或梗死体积≥70毫升)
- 已接受或计划在未来三个月内接受血管支架植入术
- 入组前3个月内发生过任何颅内出血
- 评估认为有介入治疗指征的颅内肿瘤、脑动脉瘤或动静脉畸形
- 严重活动性出血倾向或凝血功能障碍
- 心、肝、肾等重要器官严重功能不全
- 入组前1个月内接受过PCSK9单克隆抗体抑制剂治疗,或入组前6个月内接受过PCSK9 siRNA抑制剂治疗
- 对他汀类药物有明确禁忌证或他汀类药物不耐受史
- 妊娠、哺乳或计划妊娠
- 目前正在参与另一项研究
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:瑞卡西单抗联合标准治疗组
瑞卡西单抗联合标准疗法
|
Recaticimab (450 mg single dose, subcutaneous injection) combined with standard therapy recommended by the AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke 2026 and the Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023.
|
|
安慰剂比较:Recaticimab's placebo in combination with standard therapy group
Recaticimab's placebo in combination with standard therapy
|
The placebo and investigational ricaximab were identical in appearance, packaging, labeling, administration method, and dosing frequency, managed through a unified production and coding system.
Standard treatment followed the recommendations outlined in the "AHA/ASA Guidelines for the Early Management of Acute Ischemic Stroke 2026" and the "Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2023."
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of participants with functional independence, defined as a modified Rankin Scale score of 0-2, at Day 90
大体时间:Day 90 (±7 days) after randomization
|
The modified Rankin Scale (mRS) is a 7-category ordinal scale ranging from 0 (no symptoms) to 6 (death), with lower scores indicating better functional status.
This outcome is the proportion of participants with an mRS score of 0-2, representing functional independence.
Participants who die before the Day 90 assessment will be assigned an mRS score of 6.
The assessment will be performed by trained assessors blinded to treatment allocation.
|
Day 90 (±7 days) after randomization
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of participants with an excellent functional outcome, defined as an mRS score of 0-1, at Day 90
大体时间:Day 90 (±7 days) after randomization
|
The mRS ranges from 0 (no symptoms) to 6 (death), with lower scores indicating better functional status.
This outcome is the proportion of participants with an mRS score of 0-1, representing an excellent functional outcome.
Participants who die before the assessment will be assigned an mRS score of 6.
|
Day 90 (±7 days) after randomization
|
|
Distribution of modified Rankin Scale (mRS) scores at Day 90
大体时间:Day 90 (±7 days) after randomization
|
The ordinal distribution of mRS scores across all seven categories will be assessed.
The mRS ranges from 0 (no symptoms) to 6 (death), with lower scores indicating better functional status.
The outcome will evaluate a shift toward better functional outcomes across the full mRS distribution.
|
Day 90 (±7 days) after randomization
|
|
Incidence of any stroke through Day 90
大体时间:From randomization through Day 90
|
Proportion of participants who experience an adjudicated stroke after randomization, including either ischemic stroke or hemorrhagic stroke.
Suspected events will be reviewed by an independent Clinical Event Committee blinded to treatment allocation.
|
From randomization through Day 90
|
|
Incidence of ischemic stroke through Day 90
大体时间:From randomization through Day 90
|
Proportion of participants who experience an adjudicated ischemic stroke after randomization.
Ischemic stroke is defined as a new focal neurological injury attributable to cerebral ischemia, supported by clinical findings and/or imaging evidence of acute cerebral infarction, and not explained by a nonischemic cause.
Events will be adjudicated by an independent blinded Clinical Event Committee.
|
From randomization through Day 90
|
|
Incidence of composite vascular events through Day 90
大体时间:From randomization through Day 90
|
Proportion of participants who experience at least one component of the composite endpoint after randomization.
The composite endpoint includes any stroke, myocardial infarction, or vascular death.
Events will be adjudicated by an independent Clinical Event Committee blinded to treatment allocation.
|
From randomization through Day 90
|
|
Barthel Index score at Day 90
大体时间:Day 90 (±7 days) after randomization
|
Activities of daily living will be assessed using the Barthel Index.
The total score ranges from 0 to 100, with higher scores indicating greater independence in activities of daily living and better functional status.
|
Day 90 (±7 days) after randomization
|
|
Health-related quality of life assessed using the EQ-5D-5L at Day 90
大体时间:Day 90 (±7 days) after randomization
|
Health-related quality of life will be assessed using the European Quality of Life 5-Dimension 5-Level instrument.
The descriptive system assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, with five levels of severity for each dimension.
Overall self-rated health will also be assessed using the EQ visual analogue scale, ranging from 0 (worst imaginable health) to 100 (best imaginable health).
|
Day 90 (±7 days) after randomization
|
|
National Institutes of Health Stroke Scale score at Day 7 or hospital discharge
大体时间:Day 7 (±2 days) after randomization or at hospital discharge, whichever occurs first
|
Neurological impairment will be assessed using the National Institutes of Health Stroke Scale (NIHSS).
The NIHSS ranges from 0 to 42, with higher scores indicating greater neurological impairment.
|
Day 7 (±2 days) after randomization or at hospital discharge, whichever occurs first
|
|
Change from baseline in NIHSS score at Day 7 or hospital discharge
大体时间:From baseline to Day 7 (±2 days) after randomization or hospital discharge, whichever occurs first
|
Change in NIHSS score will be calculated as the follow-up NIHSS score minus the baseline NIHSS score.
The NIHSS ranges from 0 to 42, with higher scores indicating greater neurological impairment.
A negative change indicates neurological improvement, whereas a positive change indicates neurological worsening.
|
From baseline to Day 7 (±2 days) after randomization or hospital discharge, whichever occurs first
|
|
Proportion of participants achieving an LDL-C level below 1.4 mmol/L at Day 7 or hospital discharge
大体时间:Day 7 (±2 days) after randomization or at hospital discharge, whichever occurs first
|
Proportion of participants whose measured low-density lipoprotein cholesterol (LDL-C) concentration is below 1.4 mmol/L at the scheduled assessment.
|
Day 7 (±2 days) after randomization or at hospital discharge, whichever occurs first
|
|
Proportion of participants achieving an LDL-C level below 1.8 mmol/L at Day 7 or hospital discharge
大体时间:Day 7 (±2 days) after randomization or at hospital discharge, whichever occurs first
|
Proportion of participants whose measured low-density lipoprotein cholesterol (LDL-C) concentration is below 1.8 mmol/L at the scheduled assessment.
|
Day 7 (±2 days) after randomization or at hospital discharge, whichever occurs first
|
|
Change from baseline in LDL-C level at Day 7 or hospital discharge
大体时间:From baseline to Day 7 (±2 days) after randomization or hospital discharge, whichever occurs first
|
Change in LDL-C concentration will be calculated as the follow-up LDL-C value minus the baseline value and reported in mmol/L.
A negative value indicates a reduction in LDL-C from baseline.
|
From baseline to Day 7 (±2 days) after randomization or hospital discharge, whichever occurs first
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from baseline in NIHSS score at 24 hours
大体时间:From baseline to 24 hours after randomization, with an allowable assessment window of -2 to +12 hours
|
Change in NIHSS score will be calculated as the 24-hour NIHSS score minus the baseline NIHSS score.
The NIHSS ranges from 0 to 42, with higher scores indicating greater neurological impairment.
A negative change indicates neurological improvement.
|
From baseline to 24 hours after randomization, with an allowable assessment window of -2 to +12 hours
|
|
Cerebral infarct volume at Day 7 or hospital discharge
大体时间:Day 7 (±2 days) after randomization or at hospital discharge, whichever occurs first
|
Cerebral infarct volume will be quantified in milliliters using follow-up CT or MRI and assessed by a blinded core imaging laboratory.
Lower infarct volumes indicate less extensive ischemic brain injury.
|
Day 7 (±2 days) after randomization or at hospital discharge, whichever occurs first
|
|
Cerebral perfusion parameters at Day 7 or hospital discharge
大体时间:Day 7 (±2 days) after randomization or at hospital discharge, whichever occurs first
|
Prespecified quantitative cerebral perfusion parameters derived from CT perfusion or MR perfusion imaging will be assessed by a blinded core imaging laboratory.
|
Day 7 (±2 days) after randomization or at hospital discharge, whichever occurs first
|
|
Serum interleukin-6 concentration at Day 7 or hospital discharge
大体时间:Day 7 (±2 days) after randomization or at hospital discharge, whichever occurs first
|
Serum interleukin-6 concentration will be measured as a marker of systemic inflammation.
Higher concentrations indicate greater inflammatory activity.
Testing will be performed according to the prespecified laboratory procedures.
|
Day 7 (±2 days) after randomization or at hospital discharge, whichever occurs first
|
|
High-sensitivity C-reactive protein concentration at Day 7 or hospital discharge
大体时间:Day 7 (±2 days) after randomization or at hospital discharge, whichever occurs first
|
High-sensitivity C-reactive protein concentration will be measured as a marker of systemic inflammation.
Higher concentrations indicate greater inflammatory activity.
|
Day 7 (±2 days) after randomization or at hospital discharge, whichever occurs first
|
|
Incidence of any stroke through 1 year
大体时间:From randomization through 1 year
|
Proportion of participants who experience an adjudicated ischemic or hemorrhagic stroke after randomization.
Events will be reviewed by an independent Clinical Event Committee blinded to treatment allocation.
|
From randomization through 1 year
|
|
Incidence of ischemic stroke through 1 year
大体时间:From randomization through 1 year
|
Proportion of participants who experience an adjudicated ischemic stroke after randomization.
Events will be reviewed by an independent Clinical Event Committee blinded to treatment allocation.
|
From randomization through 1 year
|
|
Incidence of composite vascular events through 1 year
大体时间:From randomization through 1 year
|
Proportion of participants who experience at least one component of the composite endpoint, defined as any stroke, myocardial infarction, or vascular death.
Events will be adjudicated by an independent blinded Clinical Event Committee.
|
From randomization through 1 year
|
|
Health-related quality of life assessed using the EQ-5D-5L at 1 year
大体时间:At 1 year after randomization
|
Health-related quality of life will be assessed using the EQ-5D-5L descriptive system, covering mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Overall self-rated health will also be assessed using the EQ visual analogue scale ranging from 0 to 100, with higher scores indicating better perceived health.
|
At 1 year after randomization
|
|
Barthel Index score at 1 year
大体时间:At 1 year after randomization
|
Activities of daily living will be assessed using the Barthel Index.
The total score ranges from 0 to 100, with higher scores indicating greater independence and better functional status.
|
At 1 year after randomization
|
|
Incidence of moderate-to-severe symptomatic intracranial hemorrhage within 72 hours
大体时间:From randomization through 72 hours after randomization
|
Proportion of participants with symptomatic intracranial hemorrhage according to the modified Heidelberg criteria.
The event must include imaging-confirmed intracranial hemorrhage, an increase of at least 4 points in the total NIHSS score compared with baseline or a previously recorded NIHSS score, and neurological deterioration that cannot be explained by a cause other than the intracranial hemorrhage.
Qualifying hemorrhage types include parenchymal hematoma type 1 or 2, remote intracranial hemorrhage, subarachnoid hemorrhage, intraventricular hemorrhage, or subdural hemorrhage.
|
From randomization through 72 hours after randomization
|
|
All-cause mortality through Day 90
大体时间:From randomization through Day 90
|
Proportion of participants who die from any cause after randomization and through Day 90.
Death will be recorded as an mRS score of 6.
|
From randomization through Day 90
|
|
Incidence of adverse events through Day 90
大体时间:From administration of the study intervention through Day 90 after randomization
|
Proportion of participants who experience at least one adverse event after administration of the study intervention.
Adverse events will be recorded with respect to onset, duration, severity, relationship to the study intervention, action taken, and outcome, and will be coded using the Medical Dictionary for Regulatory Activities.
|
From administration of the study intervention through Day 90 after randomization
|
|
Incidence of serious adverse events through Day 90
大体时间:From administration of the study intervention through Day 90 after randomization
|
Proportion of participants who experience at least one serious adverse event.
A serious adverse event is an event that results in death, is life-threatening, requires inpatient hospitalization or prolongation of hospitalization, results in persistent or significant disability, causes a congenital anomaly or birth defect, or is considered an important medical event requiring intervention to prevent a serious outcome.
|
From administration of the study intervention through Day 90 after randomization
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
合作者
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
- Liu L, Chen W, Zhou H, Duan W, Li S, Huo X, Xu W, Huang L, Zheng H, Liu J, Liu H, Wei Y, Xu J, Wang Y; Chinese Stroke Association Stroke Council Guideline Writing Committee. Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of clinical management of ischaemic cerebrovascular diseases. Stroke Vasc Neurol. 2020 Jun;5(2):159-176. doi: 10.1136/svn-2020-000378. Epub 2020 Jun 18.
- Gutierrez J, Turan TN, Hoh BL, Chimowitz MI. Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment. Lancet Neurol. 2022 Apr;21(4):355-368. doi: 10.1016/S1474-4422(21)00376-8. Epub 2022 Feb 7.
- Zhao W, Li S, Li C, Wu C, Wang J, Xing L, Wan Y, Qin J, Xu Y, Wang R, Wen C, Wang A, Liu L, Wang J, Song H, Feng W, Ma Q, Ji X; TREND Investigators. Effects of Tirofiban on Neurological Deterioration in Patients With Acute Ischemic Stroke: A Randomized Clinical Trial. JAMA Neurol. 2024 Jun 1;81(6):594-602. doi: 10.1001/jamaneurol.2024.0868.
- Tao C, Liu T, Cui T, Liu J, Li Z, Ren Y, Zhao X, Xie F, Li J, Wang H, Huang L, Li J, Wen J, Zeng J, Zhu J, Li Z, Li D, Hu X, Huang B, Wang J, Zhang C, Ye B, Hou Y, Gan Y, Sun H, Guan F, Shao Y, Liu Z, Ou Z, Fan S, Wang Y, Zhai H, Ni C, Wang H, Zhang C, Zhao Y, Wang G, Zhu Y, Li R, Sun J, Hu H, Cui J, Wang L, Zhang C, Song J, Jing X, Wang A, Wang J, Xu P, Qureshi AI, Nguyen TN, Nogueira RG, Saver JL, Hu W; ASSET-IT Investigators. Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke. N Engl J Med. 2025 Sep 25;393(12):1191-1201. doi: 10.1056/NEJMoa2503678. Epub 2025 Jul 4.
- Wang C, Gu H, Huo X, Yuan B, Li S, Xu J, Jiang Y, Jing J, Yao X, Li Z, Long F, Ma Z, Zhuang X, Xu L, Jin Y, Huang W, Zhang Y, Wen J, Wang A, Pan Y, Ye W, Yu W, Cheng A, Wang M, Dong Q, Xu A, Wang N, Yang Y, Meng X, Liu L, Zhao X, Li H, Miao Z, Li Z, Wang Y; TASTE-2 investigators. Edaravone dexborneol versus placebo on functional outcomes in patients with acute ischaemic stroke undergoing endovascular thrombectomy (TASTE-2): randomised controlled trial. BMJ. 2026 Jan 7;392:e086850. doi: 10.1136/bmj-2025-086850.
- Kim J, Hong U, Yoon CW, Bae JW, Rha JH, Park HK. PCSK9 inhibitor in acute ischemic stroke patient receiving mechanical thrombectomy: early outcomes and safety. Front Neurol. 2024 May 16;15:1375609. doi: 10.3389/fneur.2024.1375609. eCollection 2024.
- Prabhakaran S, Gonzalez NR, Zachrison KS, Adeoye O, Alexandrov AW, Ansari SA, Chapman S, Czap AL, Dumitrascu OM, Ishida K, Jadhav AP, Johnson B, Johnston KC, Khatri P, Kimberly WT, Lee VH, Leslie-Mazwi TM, Mac Grory B, Madsen TE, Menon B, Mistry EA, Park S, Parker S, Perez de la Ossa N, Reeves M, Saiz T, Scott PA, Schwartzberg D, Sheth SA, Sporns PB, Times S, Tjoumakaris S, Wolfe SQ, Yaghi S; Peer Review Committee. 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2026 Jan 26. doi: 10.1161/STR.0000000000000513. Online ahead of print.
- Sun Y, Lv Q, Guo Y, Wang Z, Huang R, Gao X, Han Y, Yao Z, Zheng M, Luo S, Li Y, Gu X, Zhang Y, Wang J, Hong L, Ma X, Su G, Sheng J, Lai C, Shen A, Wang M, Zhang W, Wu S, Zheng Z, Li J, Zhong T, Wang Y, He L, Du X, Ma CS. Recaticimab as Add-On Therapy to Statins for Nonfamilial Hypercholesterolemia: The Randomized, Phase 3 REMAIN-2 Trial. J Am Coll Cardiol. 2024 Nov 12;84(20):2037-2047. doi: 10.1016/j.jacc.2024.09.012.
- Xu M, Wang Z, Zhang Y, Liu Y, Huang R, Han X, Yao Z, Sun J, Tian F, Hu X, Ma L, Lai C, Zhang X, Sheng J, Han Q, Jin C, Luo L, Zhao R, Li L, Xu B, Yin D, Luo S, Ge X, Liu Z, Yang P, Huang Z, Li T, Feng W, Wu Y, Ling Z, Ma L, Lv C, Deng C, Wei W, Wang Y, Yan L, Ge J; REMAIN-1 Investigators. Recaticimab Monotherapy for Nonfamilial Hypercholesterolemia and Mixed Hyperlipemia: The Phase 3 REMAIN-1 Randomized Trial. J Am Coll Cardiol. 2024 Nov 12;84(20):2026-2036. doi: 10.1016/j.jacc.2024.07.035. Epub 2024 Oct 9.
- Liu J, Li Y, Tian W, Cao H, Li X, Cheng L, Ji X, Liu J. Effects of PCSK9 inhibitor evolocumab on preventing early neurological deterioration in acute ischemic stroke patients with or without large artery atherosclerosis: a subgroup analysis of a randomized trial. BMC Neurol. 2025 Oct 17;25(1):431. doi: 10.1186/s12883-025-04434-8.
- Wu L, Zhang B, Li C, Zhuang Z, Liu K, Chen H, Zhu S, Zhu J, Dai Z, Huang H, Jiang Y. PCSK9 inhibitors reduced early recurrent stroke in patients with symptomatic intracranial atherosclerotic stenosis. J Neurol Neurosurg Psychiatry. 2024 May 14;95(6):529-535. doi: 10.1136/jnnp-2023-332392.
- Tian W, Cao H, Li X, Gong X, Yu X, Li D, Xie J, Bai Y, Zhang D, Li X, Xu P, Liu J, Zhang B, Ji X, Dong H. Adjunctive PCSK9 Inhibitor Evolocumab in the Prevention of Early Neurological Deterioration in Non-cardiogenic Acute Ischemic Stroke: A Multicenter, Prospective, Randomized, Open-Label, Clinical Trial. CNS Drugs. 2025 Feb;39(2):197-208. doi: 10.1007/s40263-024-01145-5. Epub 2025 Jan 5.
- Zeng W, Zhou F, Zhao H, Wang Y, Chen J, Lu J, Zheng D, Kuang J, Yuan D, Zhou J, Shi C, Zhao X, Leng X, Yan B, Tan Z. Evaluation of Intensive Statins and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Intracranial Artery Plaque Stability: A Prospective Single-Arm Study. J Am Heart Assoc. 2025 Jan 21;14(2):e035651. doi: 10.1161/JAHA.124.035651. Epub 2025 Jan 17.
- Hu X, Liu Y, Yuan W, Zhang Z, Li S, Cheng A, Yu Q, Guo H, Zou Y, Li M, Liu C, Xu Y, Xu W. Evolocumab Added to Statin Is Associated With Intracranial Atherosclerotic Plaque Regression Compared With Statin Alone. J Am Heart Assoc. 2025 Aug 19;14(16):e041251. doi: 10.1161/JAHA.124.041251. Epub 2025 Aug 18.
- Jukema JW, Zijlstra LE, Bhatt DL, Bittner VA, Diaz R, Drexel H, Goodman SG, Kim YU, Pordy R, Reiner Z, Roe MT, Tse HF, Montenegro Valdovinos PC, White HD, Zeiher AM, Szarek M, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Investigators. Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. Circulation. 2019 Dec 17;140(25):2054-2062. doi: 10.1161/CIRCULATIONAHA.119.043826. Epub 2019 Nov 11.
- Wang L, Wang Z, Shi J, Jiang Q, Wang H, Li X, Hao D. Inhibition of proprotein convertase subtilisin/kexin type 9 attenuates neuronal apoptosis following focal cerebral ischemia via apolipoprotein E receptor 2 downregulation in hyperlipidemic mice. Int J Mol Med. 2018 Oct;42(4):2098-2106. doi: 10.3892/ijmm.2018.3797. Epub 2018 Jul 31.
- Zheng Y, Zhu T, Li G, Xu L, Zhang Y. PCSK9 inhibitor protects against ischemic cerebral injury by attenuating inflammation via the GPNMB/CD44 pathway. Int Immunopharmacol. 2024 Jan 5;126:111195. doi: 10.1016/j.intimp.2023.111195. Epub 2023 Dec 4.
- Luo Y, Yuan L, Liu Z, Dong W, Huang L, Liao A, Xie Y, Liu R, Lan W, Cai Y, Zhu W. Inhibition of PCSK9 Protects against Cerebral Ischemia-Reperfusion Injury via Attenuating Microcirculatory Dysfunction. Neurochem Res. 2024 Nov 16;50(1):10. doi: 10.1007/s11064-024-04272-z.
- Punch E, Klein J, Diaba-Nuhoho P, Morawietz H, Garelnabi M. Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis. J Am Heart Assoc. 2022 Feb;11(3):e023328. doi: 10.1161/JAHA.121.023328. Epub 2022 Jan 20.
- Park TH, Lee JK, Park MS, Park SS, Hong KS, Ryu WS, Kim DE, Park MS, Choi KH, Kim JT, Kang J, Kim BJ, Han MK, Lee J, Cha JK, Kim DH, Kim JG, Lee SJ, Cho YJ, Kwon JH, Shin DI, Yeo MJ, Sohn SI, Hong JH, Lee JS, Choi JC, Kim WJ, Lee BC, Yu KH, Oh MS, Park JM, Kang K, Lee KB, Lee J, Gorelick PB, Bae HJ. Neurologic deterioration in patients with acute ischemic stroke or transient ischemic attack. Neurology. 2020 Oct 20;95(16):e2178-e2191. doi: 10.1212/WNL.0000000000010603. Epub 2020 Aug 14.
- Glavan M, Liu J, Sampaio Silva G, Nguyen TN, Zhou J, Sestan N, Kimberly WT, Sheth KN. Endovascular thrombectomy for acute stroke: evolving eligibility criteria and adjunct therapies. Lancet Neurol. 2026 Jan;25(1):61-76. doi: 10.1016/S1474-4422(25)00356-4.
- 《中国卒中中心报告》编写组. 《中国卒中中心报告 2020》概要.中国脑血管病杂志. 2021;18(11):737-743.
- Writing Committee for the PEARL Investigators; Yang X, He X, Xu Y, Pan D, Li K, Chen Y, Zhu Y, Pan Y, Yi T, Zhang M, Peng H, Huang W, Li D, Feng J, Chen J, Lu W, Liao B, Xie Y, Liao B, Yang L, Tang L, Han B, Liu Y, Lin P, Chen J, Liang Y, Li D, Weng G, Huang H, Li H, Li C, Peng Z, Li H, He B, Xue R, Bao M, Sun H, Hou H, Zhou H, Xiao Y, Li J, Zhang W, Chen X, Yan W, Pi Y, Deng Z, Wang J, Xie D, Liu M, Li H, Peng Q, Fang W, Lin X, Chen Z, Li H, Lin Y, Lin Q, Xiao S, Miao Z, Wang D, Nguyen TN, Nogueira RG, Liu Y, Tang Y; PEARL investigators. Intra-Arterial Alteplase After Successful Endovascular Reperfusion in Acute Stroke: The PEARL Randomized Clinical Trial. JAMA. 2025 Oct 13;334(19):1728-39. doi: 10.1001/jama.2025.16876. Online ahead of print.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年9月1日
初级完成 (估计的)
2028年12月31日
研究完成 (估计的)
2029年12月31日
研究注册日期
首次提交
2026年3月7日
首先提交符合 QC 标准的
2026年3月11日
首次发布 (实际的)
2026年3月12日
研究记录更新
最后更新发布 (实际的)
2026年7月15日
上次提交的符合 QC 标准的更新
2026年7月14日
最后验证
2026年4月1日
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 1-24PJ2600
- 2024ZD0521605 (其他赠款/资助编号:the Noncommunicable Chronic Diseases-National Science and Technology Major Project)
- 82025013 (其他赠款/资助编号:the National Science Fund for Distinguished Young Scholars)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
未定
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.